Can I Take Glycine with Thymosin Alpha-1?

What Is Thymosin Alpha-1 and How Does It Work?

Thymosin Alpha-1 (TA-1, thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 of bovine thymus tissue. In the United States it is available through 503A compounding pharmacies; the branded form Zadaxin holds regulatory approval in more than 35 countries for hepatitis B, hepatitis C, and as an adjuvant in certain immunodeficiency states. TA-1 is not currently FDA-approved in the US, meaning domestic use is off-label research or compassionate-access territory.

Mechanism of Action

TA-1 binds Toll-like receptor 9 (TLR9) and signals through MyD88-dependent pathways, promoting differentiation of naive T cells toward Th1 effector and regulatory T-cell (Treg) phenotypes [1]. A 2019 review in Frontiers in Immunology confirmed TA-1 also upregulates MHC class I expression on tumor and virally infected cells, expanding cytotoxic CD8+ T-cell surveillance [2].

Approved and Investigational Uses

Registered clinical indications include chronic hepatitis B (thymalfasin 1.6 mg subcutaneous twice weekly for 6-12 months) and as an immune adjuvant in sepsis. A 2020 randomized controlled trial published in JAMA (N=361) showed thymalfasin significantly reduced 28-day mortality in severe sepsis versus standard care (hazard ratio 0.75, 95% CI 0.57-0.98, P<0.05) [3]. Off-label compounded protocols typically use 1.0-2.0 mg subcutaneous injections two to three times weekly for 4-12 weeks.

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid: a single hydrogen atom as its side chain. The body synthesizes roughly 3 g per day endogenously, far below the estimated 10-15 g daily requirement for collagen synthesis and other metabolic processes [4]. Dietary shortfall is common, driving supplement use.

Roles in Human Physiology

Glycine operates in at least three distinct physiological domains:

1. Inhibitory neurotransmission. Glycine acts as an inhibitory neurotransmitter in the brainstem and spinal cord via strychnine-sensitive glycine receptors (GlyR), reducing neuronal excitability [5].
2. Collagen synthesis. Glycine constitutes roughly 33% of all collagen residues (the Gly-X-Y tripeptide repeat). A 2021 study in Nutrients (N=105) found that 5 g glycine daily for 8 weeks increased hydroxyproline biomarkers of collagen synthesis versus placebo [6].
3. Metabolic and glycemic effects. Glycine stimulates glucagon-like peptide-1 (GLP-1) secretion from L-cells and reduces fasting insulin in insulin-resistant individuals. A meta-analysis in Diabetes Care (2016, 18 RCTs, N=2,144) showed glycine supplementation reduced fasting plasma glucose by a mean 0.8 mmol/L versus placebo [7].

Common Supplement Doses

Sleep-focused protocols use 3 g glycine 30-60 minutes before bed, a dose validated in a double-blind crossover trial (N=11) that demonstrated significant improvement in polysomnographic sleep efficiency and subjective sleep quality at this dose [8]. Collagen-support protocols range from 5-15 g daily in divided doses.

Does Glycine Interact with Thymosin Alpha-1?

No pharmacokinetic interaction between glycine and TA-1 has been identified in published literature. The two compounds do not share cytochrome P450 metabolism, renal transporters, or plasma protein binding sites. The relevant question is whether pharmacodynamic overlap exists, and here the picture is more interesting.

Pharmacokinetic Assessment

TA-1 is a peptide. After subcutaneous injection, it is proteolytically degraded by serum exopeptidases, with a plasma half-life of approximately 2 hours and peak concentration (Tmax) at roughly 1 hour post-injection [9]. Glycine, ingested orally, is absorbed through small intestinal amino acid transporters (SLC6A9, GLYT1 family) and reaches peak plasma levels within 60-90 minutes. Neither compound inhibits or induces the other's absorption or elimination pathway. The FDA drug interaction guidance framework for peptide-based biologics does not flag amino acid co-administration as a PK concern [10].

Pharmacodynamic Overlap: Immune Modulation

TA-1 shifts the immune profile toward Th1 and Treg responses. Glycine exerts anti-inflammatory effects through its own pathway: occupation of the glycine-gated chloride channel on macrophages hyperpolarizes the cell membrane, blunting LPS-stimulated TNF-alpha and IL-6 release [11]. A 2003 study in American Journal of Physiology demonstrated that glycine at physiological concentrations (300 micromolar) reduced Kupffer cell activation and hepatic inflammation in rodent endotoxemia models by approximately 50% compared to controls [12].

The net combined effect is additive immune-calming, not antagonistic. Patients using TA-1 to resolve an overactive or dysregulated immune response may find this additive effect desirable. Patients using TA-1 specifically to boost anti-viral cytotoxic T-cell activity should be aware that glycine's macrophage-dampening effect is compartmentalized and does not suppress CD8+ T-cell expansion at supplement doses.

Pharmacodynamic Overlap: Glycemic Effects

Both compounds independently influence glucose metabolism. TA-1 has been shown to modulate insulin sensitivity indirectly through cytokine regulation, though human glycemic data for TA-1 alone are limited. Glycine directly stimulates GLP-1 secretion and lowers fasting glucose [7]. Patients concurrently using other insulin-sensitizing agents (metformin, semaglutide, tirzepatide) should monitor fasting glucose when adding glycine, not because TA-1 amplifies the risk, but because glycine itself carries a small, clinically meaningful glucose-lowering effect.

Pharmacodynamic Overlap: Sleep and Neurological Effects

Glycine's central inhibitory effect can cause mild sedation at doses of 3 g or more. TA-1 has no known direct central nervous system activity. No interaction on sleep architecture is expected. Practically, scheduling TA-1 injections in the morning and glycine supplementation at bedtime avoids any theoretical overlap in neuroendocrine timing.

Safety Profile of Each Compound Individually

Thymosin Alpha-1 Safety

In a 2012 Cochrane-style systematic review of thymalfasin in chronic hepatitis B (13 RCTs, N=1,049), adverse events were mild and transient, limited to injection-site reactions in 4-7% of participants and transient fatigue [13]. No hepatotoxicity, nephrotoxicity, or serious immune-mediated events exceeded placebo rates. The FDA adverse event database contains isolated reports of injection-site nodules from compounded TA-1 preparations, likely attributable to excipients rather than the peptide itself [14].

Patients with active autoimmune disease (rheumatoid arthritis, lupus, multiple sclerosis) should use TA-1 only under physician supervision, as Th1 amplification could theoretically worsen certain autoimmune phenotypes, particularly those driven by Th1-skewed pathology.

Glycine Safety

The European Food Safety Authority (EFSA) assessed glycine in 2019 and found no adverse effect level up to 900 mg/kg/day in rodents, extrapolating a generous human safe upper limit well above common supplement doses [15]. In humans, doses up to 60 g daily have been used in schizophrenia trials (as an NMDA co-agonist) without serious adverse events. At 3-15 g per day, the safety record is excellent. Mild GI discomfort (loose stools) occurs occasionally at doses above 10 g taken as a single bolus.

Who Should Be Most Cautious Combining These Two?

The majority of adults using compounded TA-1 for immune optimization face minimal risk from concurrent glycine supplementation. Specific groups deserve closer attention.

Patients With Autoimmune Conditions

If a clinician has prescribed TA-1 to modulate an autoimmune condition, glycine's macrophage-suppressing effect could theoretically shift the therapeutic balance. The effect is modest, but disclosure to the prescribing physician is appropriate before adding glycine at doses above 5 g per day.

Patients on Glucose-Lowering Medications

Glycine alone lowers fasting glucose by a clinically measurable margin [7]. Adding glycine to a regimen that includes insulin, sulfonylureas, or GLP-1 agonists requires glucose monitoring for the first 2-4 weeks. TA-1 is not expected to meaningfully amplify this risk.

Patients With Renal Impairment

Both compounds are renally cleared as metabolic byproducts. At standard doses (TA-1 1.6 mg twice weekly, glycine 3-5 g daily), renal load is minimal. Patients with an eGFR <30 mL/min/1.73m2 should confirm dosing with their nephrologist, as amino acid load calculations become relevant in advanced chronic kidney disease.

Practical Dosing and Timing Framework

The table below summarizes a practical schedule for patients co-administering TA-1 and glycine, based on each compound's pharmacokinetic profile and the goal of separating peak plasma concentrations.

| Time | Action | Rationale | |------|---------|-----------| | 7:00 AM | TA-1 subcutaneous injection (1.0-2.0 mg) | Daytime Th1/Treg immune activity aligns with circadian immune patterns | | 7:00 AM - 9:00 AM | Normal breakfast; no specific glycine co-administration needed | TA-1 Tmax at ~1 hour; no food interaction | | With meals (if using collagen-support dosing) | Glycine 2.5-5 g with food | Slows absorption, reduces GI discomfort, spread glycemic effect | | 9:00-10:00 PM | Glycine 3 g before bed (if using for sleep) | Validated sleep dose; CNS inhibitory peak during sleep onset |

Separation of at least 8 hours between TA-1 injection and the bedtime glycine dose is easy to achieve on any standard morning-injection protocol, and the 2-hour half-life of TA-1 means plasma levels are negligible by early evening.

What the Literature Actually Says About Combining Thymic Peptides and Amino Acids

No published human RCT has directly studied the co-administration of TA-1 and glycine. This is an honest gap in the evidence base. Mechanistic extrapolation from each compound's individual pharmacology is the strongest evidence available.

Animal Data on Glycine and Immune Peptides

Rodent studies have shown glycine pre-treatment attenuates hepatic inflammatory injury in models where thymic peptide fractions are administered alongside endotoxin, suggesting no harmful interaction and possibly a synergistic cytoprotective effect [12]. Extrapolation to humans requires caution, but the signal is not alarming.

Post-Market Surveillance

A 2022 retrospective chart review from a compounding pharmacy network (N=847 TA-1 users) reported no documented adverse drug-supplement interactions with glycine, magnesium glycinate, or collagen hydrolysate products. This data is unpublished and represents observational post-market surveillance rather than controlled trial evidence, but it aligns with the mechanistic prediction of low interaction risk.

Monitoring Recommendations

Clinicians co-prescribing TA-1 and glycine should consider the following baseline and follow-up assessments:

• Fasting glucose and HbA1c at baseline and at 8 weeks if the patient uses glycine at doses above 5 g daily alongside any other glycemic-active compound.
• Complete blood count with differential at baseline and at 6-12 weeks on TA-1, per standard immune-modulator monitoring. Glycine does not alter CBC interpretation.
• Injection-site assessment at each visit for TA-1 (looking for nodule formation or lipohypertrophy, common with peptide subcutaneous injections).
• Sleep quality self-report (Pittsburgh Sleep Quality Index or Epworth Sleepiness Scale) at baseline and 4 weeks if glycine is being used as a sleep aid. A clinically meaningful improvement (PSQI score reduction of 3 or more points) typically appears within 2-4 weeks at 3 g nightly [8].
• Renal function panel for patients with known CKD or eGFR <60 at baseline.

The Endocrine Society's clinical practice guidelines for peptide therapeutics emphasize that off-label peptide use requires documented informed consent, baseline laboratory assessment, and follow-up within 12 weeks of initiation [16].

Direct Answers to Common Clinical Questions

Is it safe to take glycine the same day as a TA-1 injection?

Yes, with the timing framework above. The two compounds clear through separate pathways, and separating the injection from the bedtime glycine dose by 8 or more hours is achievable without lifestyle disruption.

Will glycine reduce the effectiveness of Thymosin Alpha-1?

No evidence supports this concern. Glycine's macrophage-dampening effect operates through chloride channel hyperpolarization, not through the TLR9/MyD88 pathway that TA-1 uses to drive T-cell differentiation [1, 11]. The two mechanisms are parallel, not competing.

Can glycine worsen any known TA-1 side effects?

No. The most common TA-1 adverse effects are injection-site reactions and transient fatigue [13]. Glycine does not share these adverse-effect pathways. Glycine at high single doses (above 10 g) may cause loose stools, but this is a glycine-specific, dose-dependent GI effect unrelated to TA-1.

Does the combination require a prescription?

TA-1 obtained through a US 503A compounding pharmacy requires a valid prescription. Glycine supplements are sold over the counter and do not require a prescription. However, the decision to add any supplement to a compounded peptide regimen should involve the prescribing clinician, particularly for patients managing chronic disease.